Navigation Links
PharmSource CMO-CDMO Database Expands Coverage to Include Approved Pharmaceutical Products: Intelligence Resource for Analyzing Bio/Pharmaceutical Contract Manufacturing

Fairfax, VA (PRWEB) July 16, 2013

The newest CMO-CDMO database offering from PharmSource is an upgrade to the widely respected PharmSource ADVANTAGE online service, and is a ready resource for deep insight into bio/pharmaceutical contract manufacturing trends based on key data that - until now - were difficult to find in a single, highly dependable source. New features in PharmSources' STRATEGIC ADVANTAGE online service include research capabilities to:

  •     Identify approved pharmaceutical products by CMO/manufacturer, applicant name or by product characteristics (including dosage form, route of administration, injectable packaging type, API, and more).
  •     Conduct searches for approved products by proprietary or generic product names, sponsor type, FDA and EU approvals, etc.
  •     Research pharmaceutical Merger & Acquisition activity by transaction nature, buyer or seller.
  •     Identify contract manufacturers by ownership type, including: government agency, not-for profit, private – management owned, private – venture capital owned, public company, unit of public company, university, etc. Search results include data on contract revenue ranges, when available.
  •     Download all search results into Excel, including side-by-side comparisons of contractor capabilities. This new feature is extremely valuable, as it allows users to freely use PharmSource Strategic Advantage data as part of their vital internal tool-kit for understanding the industry and trends.

PharmSource STRATEGIC ADVANTAGE service adds important support for sourcing and procurement executives who regularly make outsourcing decisions and assess contract manufacturing partners. It gives them an excellent resource for conducting high-level strategic analyses, including the ability to quickly and easily compare contract manufacturers, both in the detailed manufacturing capabilities they offer, and in their product experience.

Contract manufacturers also find great value in PharmSource STRATEGIC ADVANTAGE as a primary strategic planning and benchmarking resource to assess comparative capabilities, performance and product history. Just as important, it provides critical insight into likely future resource needs, identifying which pharmaceutical dosage forms have the greatest likelihood of being outsourced, and other critically important trends that drive major business decisions. It also is a resource for making trusted referrals.

For a limited time, a complimentary test-drive of PharmSource STRATEGIC ADVANTAGE is being offered to qualified companies. For more information, contact PharmSource's Customer Service Department at +1-703-383-4903, ext. 101 / info[at]pharmsource[dot]com.

About PharmSource

PharmSource brings together buyers and sellers of contract services for the development of drugs, medical devices and diagnostics. A trusted provider of global market and business intelligence since 1996, PharmSource publishes reports and databases, and conducts surveys and analyses related to industry contract service activities and trends.

+1-703-383-4903 Phone (USA, eastern time-zone)

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. PharmSource Lead Sheet Adds Coverage of Medical Devices and Diagnostics
2. Waters and NIBRT Complete Work on Worlds First UPLC Glycan Database
3. HemoShear Partners with Expression Analysis (EA) to Develop a Human Drug-Induced Vascular Response Database
4. Elsevier Launches a New Product Literature Database Solution for Life Science Professionals
5. Conflict of Interest Management Tool Links with ProPublicas "Dollars for Docs" Database
6. Launches as a Collective Database of Artery Health Research
7. WCCT Global (WCCT) & Verified Clinical Trials (VCT) Announce Medication Adherence Documentation Capabilities Have Been Added to the VCT Clinical Trials Database Registry
8. Verified Clinical Trials Will Exhibit at the Annual 2013 SCOPE Summit to Discuss the Professional Research Subject and the Clinical Trial Database Registry
9. ChemAxons Extends PubChem Database With Crowd-Sourced Chemistry From the Web
10. Verified Clinical Trials Exhibits at the Annual 2013 Partnerships In Clinical Trials to Discuss the Professional Research Subject and the Clinical Trial Database Registry
11. UV Flu Technologies Expands Its International Footprint
Post Your Comments:
(Date:6/23/2016)... ... ... Supplyframe, the Industry Network for electronics hardware design and ... in Pasadena, Calif., the Design Lab’s mission is to bring together inventors and ... brought to market. , The Design Lab is Supplyframe’s physical representation of one ...
(Date:6/23/2016)... ... 2016 , ... In a new case report published today in STEM CELLS ... developed lymphedema after being treated for breast cancer benefitted from an injection of stem ... with this debilitating, frequent side effect of cancer treatment. , Lymphedema refers ...
(Date:6/23/2016)... BEACH, Calif. , June 23, 2016  Blueprint ... new biological discoveries to the medical community, has closed ... co-founder Matthew Nunez . "We have ... us with the capital we need to meet our ... will essentially provide us the runway to complete validation ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
Breaking Biology Technology:
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
Breaking Biology News(10 mins):